Imaging Test Looks for Early Amyloid Deposits in Monoclonal Gammopathy
Tests a PET scan tracer to detect amyloid deposits in adults with monoclonal gammopathy.
Plain-language title generated from the registry record
Registry title: Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging
Key facts
- Where
- Zurich, SwitzerlandSee the site
Where in Switzerland
- University Hospital ZurichZurich, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Zurich
- Trial code
- NCT07624760
- Record updated
- 3 June 2026
- Original description
The goal of this clinical trial is to evaluate whether ¹⁸F-florbetaben PET/MR can detect systemic amyloid deposits early and noninvasively in patients with monoclonal gammopathy. The main question it aims to answer is: Can ¹⁸F-florbetaben PET/MR identify systemic amyloid deposits across clinically and histologically defined patient groups?Read full original descriptionShow less
Early Detection of Light-Chain Amyloidosis in Monoclonal Gammopathy Using 18F-Florbetaben PET/MR: a Prospective, Single-Center, Observational Study
The goal of this clinical trial is to evaluate whether ¹⁸F-florbetaben PET/MR can detect systemic amyloid deposits early and noninvasively in patients with monoclonal gammopathy. The main question it aims to answer is: Can ¹⁸F-florbetaben PET/MR identify systemic amyloid deposits across clinically and histologically defined patient groups?
Participants will:
* Be screened for eligibility and asked to sign an informed consent form * Have their vital signs measured * Receive a single intravenous injection of approximately 300 MBq ¹⁸F-florbetaben (Neuraceq®), followed by whole-body PET/MR imaging from skull base to below the kidneys. If MRI is contraindicated (e.g., pacemaker, severe claustrophobia), PET/CT will be performed instead. The scan takes approximately one hour, during which participants lie still in the scanner * Be monitored during and after the scan for any side effects or adverse events * Complete study participation at the end of the imaging session (single visit, no follow-up required)
Inclusion: Participation in the COSMO-AL study; Available biopsy test result; Written informed consent.
Exclusion: Pregnant or lactating women.